ESP Live! National Meeting Highlights at the 2014 American Academy of Pain Management – Part 1
Release Date: November 05, 2014
Expiration Date: November 05, 2015
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
This educational activity offers highlights from key sessions presented at the 2014 American Academy of Pain Management. Key thought leaders summarize the latest information in pain management today. This highlight series focuses on the latest data, on what the data means in the clinical setting, and how clinicians may effectively incorporate this information to improve patient care, and ultimately, patient outcomes.
The target audience for the accredited activity, ESP Live! National Meeting Highlights at the 2014 American Academy of Pain Management,will be pain management specialists, as well as primary care specialists, and pharmacists who provide care to patients with chronic pain.
Upon completion of this educational activity, participants should be able to:
- Summarize recent presentations regarding safety and efficacy of current and novel approaches to management of chronic pain
- Apply the clinical relevance and potential impact of these findings in the care of patients with chronic pain
- Identify key recommendations concerning approaches to therapy with opioids that minimize risk and are designed to optimize outcomes
Selective Pain Pharmacology and Interactions with Miscalculated Risks – Jeffrey Fudin, RPh, PharmD, DAAPM, FCCP
Enhancing Patient-Provider Communication to Improve Pain Outcomes – Brett B. Snodgrass, MSN, APRN, FNP-BC
Instructions for Participation and Credit
This activity is eligible for credit through November 5, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Jeffrey Fudin, RPh, PharmD, DAAPM, FCCP
Adjunct Associate Professor of Pharmacy Practice
Western New England University College of Pharmacy
Clinical Pharmacy Specialist and Director
Samuel Stratton Department of Veterans Affairs Medical Center
Albany, New York
Dr. Jeffrey Fudin received his PharmD from Albany College of Pharmacy and completed an American Cancer Society sponsored fellowship in oncology/hematology at SUNY/Upstate Medical Center. He is an adjunct associate professor of pharmacy practice at Western New England University College of Pharmacy, an adjunct assistant professor of pharmacy practice at the University of Connecticut School of Pharmacy. In addition, Dr. Fudin is a clinical pharmacy specialist and director at the Samuel Stratton Department of Veterans Affairs Medical Center in Albany New York.
Dr. Fudin is an American Academy of Pain Management diplomate, a American College of Clinical Pharmacy fellow, and founder/chairman of Professionals for Rational Opioid Monitoring & Pharmacotherapy (PROMPT), an advocacy group in favor of safe opioid prescribing by encouraging clinician education, proactive risk stratification, and appropriate therapeutic monitoring. He is section editor for Pain Medicine, and is on the editorial board of Practical Pain Management. As a peer reviewer, Dr. Fudin established American Pain Society Clinical Practice Guidelines for arthritis, for fibromyalgia, and for cancer pain and palliative care. He is an active writer and researcher on pain management issues and has been an invited speaker on pain management both nationally and internationally. Recently, Dr. Fudin has been called upon to help strategize education on proper opioid prescribing and monitoring for Risk Evaluation and Mitigation Strategies (REMS).
Brett B. Snodgrass, MSN, APRN, FNP-BC
Family Nurse Practitioner
Comprehensive Primary Care
Brett Snodgrass is certified as a family nurse practitioner and is the founder and CEO of BBS Consultants, Inc. She is a registered nurse and family nurse practitioner at Comprehensive Primary Care in Atoka and Bartlett, Tennessee, and is also an international provider of nurse practitioner certification preparation and continuing education.
Ms. Snodgrass is a legal consultant/case reviewer/expert witness for private legal practices as well as Tennessee Board of Nursing and Tennessee General Council. She also serves as a clinical expert, partnering with key medical leaders across the state to establish and implement guidelines for safe opioid prescribing in Tennessee. She is the president of the Greater Memphis Area Advanced Practice Nurses, the APRN Committee Member-at-large for the Tennessee Nurses Association, and is a member of Greater Memphis Area Advanced Practice Nurses.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-14-027-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jeffrey Fudin has received honoraria related to speakers’ bureau activities from Ortho-McNeil (Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.).
Brett Snodgrass has received honoraria related to formal advisory activities from McNEIL-PPC, Inc; the development of educational materials from CO*RE REMS; and speakers’ bureau activities from AstraZeneca, Depomed, Inc., and Iroko Pharmaceuticals, LLC.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Fudin and Ms. Snodgrass have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Fudin and Ms. Snodgrass have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Purdue Pharma L.P.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.